JP2023509402A5 - - Google Patents
Info
- Publication number
- JP2023509402A5 JP2023509402A5 JP2022539173A JP2022539173A JP2023509402A5 JP 2023509402 A5 JP2023509402 A5 JP 2023509402A5 JP 2022539173 A JP2022539173 A JP 2022539173A JP 2022539173 A JP2022539173 A JP 2022539173A JP 2023509402 A5 JP2023509402 A5 JP 2023509402A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody according
- antibody
- cancer
- fgfr2b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019127902 | 2019-12-24 | ||
| CNPCT/CN2019/127902 | 2019-12-24 | ||
| PCT/CN2020/138580 WO2021129655A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509402A JP2023509402A (ja) | 2023-03-08 |
| JP2023509402A5 true JP2023509402A5 (enExample) | 2024-01-05 |
| JP7685999B2 JP7685999B2 (ja) | 2025-05-30 |
Family
ID=76573702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539173A Active JP7685999B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230055566A1 (enExample) |
| EP (1) | EP4081546A4 (enExample) |
| JP (1) | JP7685999B2 (enExample) |
| KR (1) | KR20220119471A (enExample) |
| CN (1) | CN114901692A (enExample) |
| AR (1) | AR120883A1 (enExample) |
| AU (1) | AU2020414910A1 (enExample) |
| CA (1) | CA3160810A1 (enExample) |
| MX (1) | MX2022007959A (enExample) |
| TW (1) | TWI864207B (enExample) |
| WO (1) | WO2021129655A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7686000B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
| CA3190569A1 (en) * | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| CN119110806A (zh) * | 2022-03-28 | 2024-12-10 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN120418288A (zh) * | 2022-09-30 | 2025-08-01 | 思康睿奇(上海)药业有限公司 | FGFR2b抗体及其用途 |
| KR20250126131A (ko) * | 2022-12-28 | 2025-08-22 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 항-fgfr2b 항체 및 이의 용도 |
| CN121039158A (zh) * | 2023-03-31 | 2025-11-28 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| WO2025067442A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | 抗fgfr2抗体和包含其的多特异性结合分子 |
| TW202540177A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商蘇州創勝醫藥集團有限公司 | 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途 |
| WO2025130860A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体及其应用 |
| JP2026508860A (ja) * | 2024-01-05 | 2026-03-13 | ビーワン メディシンズ ワン ゲーエムベーハー | 抗ＦＧＦＲ２ｂ抗体、コンジュゲート、及び使用方法 |
| CN120424212A (zh) * | 2024-01-26 | 2025-08-05 | 上海安领科生物医药有限公司 | 抗FGFR2b抗体及抗体药物偶联物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2060270A3 (en) | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| SG11201403085PA (en) | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| KR102516152B1 (ko) * | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| MX2018006181A (es) | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| WO2017091429A1 (en) * | 2015-11-24 | 2017-06-01 | Eli Lilly And Company | Combination therapy for cancer |
| WO2018095932A1 (en) | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| TW201833140A (zh) * | 2017-01-09 | 2018-09-16 | 美商莫瑞麥克製藥公司 | 抗fgfr抗體及使用方法 |
-
2020
- 2020-12-23 KR KR1020227025530A patent/KR20220119471A/ko active Pending
- 2020-12-23 MX MX2022007959A patent/MX2022007959A/es unknown
- 2020-12-23 AR ARP200103628A patent/AR120883A1/es unknown
- 2020-12-23 CN CN202080089839.0A patent/CN114901692A/zh active Pending
- 2020-12-23 EP EP20904511.1A patent/EP4081546A4/en active Pending
- 2020-12-23 CA CA3160810A patent/CA3160810A1/en active Pending
- 2020-12-23 JP JP2022539173A patent/JP7685999B2/ja active Active
- 2020-12-23 AU AU2020414910A patent/AU2020414910A1/en active Pending
- 2020-12-23 WO PCT/CN2020/138580 patent/WO2021129655A1/en not_active Ceased
- 2020-12-23 US US17/788,729 patent/US20230055566A1/en active Pending
- 2020-12-24 TW TW109145973A patent/TWI864207B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509402A5 (enExample) | ||
| JP2023508174A5 (enExample) | ||
| JP7519910B2 (ja) | 抗ｍｕｃ１抗体 | |
| JP6727379B2 (ja) | Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト | |
| JP2023508173A5 (enExample) | ||
| JP2022066565A (ja) | 抗ｎｔｂ－ａ抗体ならびに関連する組成物および方法 | |
| JP7820383B2 (ja) | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| CN107406497A (zh) | 半胱氨酸连接的纳米抗体二聚体 | |
| CN119818671A (zh) | 抗SIRPα抗体及其用途 | |
| CN108290931A (zh) | 对pd-l1具有亲和力的新的多肽 | |
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| JP2024500920A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| CN119173540A (zh) | 多特异性抗体及其用途 | |
| CN121909212A (zh) | 抗cdh17抗体及其用途 | |
| JP2024020436A (ja) | Ｈｅｒ２標的化剤 | |
| CN116496404A (zh) | 靶向cd47和pd-l1的双特异性抗体及其应用 | |
| EP4007607A1 (en) | Materials and methods for polymeric antibody receptor targeting | |
| CN121263447A (zh) | Trop2抗体 | |
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| CN120641128A (zh) | 抗cd16a抗体及其用途 | |
| CN117304324A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| CN117304323A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| WO2026067461A1 (en) | Multispecific antibody protein and uses thereof | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 |